Avalon Ventures

Avalon is our principal investor and one of the longest-standing venture capital firms in San Diego. Avalon has been investing in Life Science and Information Technology opportunities since 1983 and has supported the development of over 60 early-stage companies, including; Athena Neurosciences (acquired by Elan), Onyx Pharmaceuticals, Sequana Therapeutics (acquired by Celera Genomics), Vertex Pharmaceuticals, Synaptics, Inc., Vocera Communications, Sytera Inc. (acquired by Sirion), Aurora Biosciences (acquired by Vertex), Landmark Graphics, NeoRx, and X-Ceptor (acquired by Exelixis) and Zacharon Pharmaceuticals (acquired by BioMarin). The collective market capitalization of Avalon Ventures’ portfolio companies currently exceeds $11 billion.

ResMed (NYSE: RMD and ASX: RMD.AX)

ResMed is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other respiratory disorders with annual sales in excess of $1 billion. ResMed operates in over 68 countries via 18 direct offices and a network of distributors with extensive knowledge and experience of local markets.